Citi analyst Joanne Wuensch lowered the firm’s price target on iRhythm to $110 from $144 and keeps a Neutral rating on the shares. Looking into 2023, "many headwinds remain" for the North America medical supplies and technology group, but these should ease in the second half of next year, alleviating operating margin pressures, Wuensch tells investors in a research note. Thus, the analyst is looking for the stocks "that will swim past the pandemic." She does not anticipate it will be an "easy year" to invest in medical technology, but says it "be one of recovery driven by more level-set expectations and product cycles." WWuensch upgraded Glaukos (GKOS) to Buy from Neutral on the stock pull back and ahead of new products, upgraded Becton Dickinson (BDX) to Neutral from Sell on a more reasonable relative valuation, and downgraded Baxter (BAX) to Neutral from Buy, saying "execution is key." She are also upgrading Pulmonx (LUNG) to Buy from Neutral, and opened a "Positive Catalyst Watch" on Silk Road Medic (SILK), saying upside to Q4 and 2023 guidance can continue the stock’s momentum.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRTC:
- iRhythm management to meet virtually with BTIG
- iRhythm upgraded to Peer Perform from Underperform at Wolfe Research
- New Research Confirms that Zio® by iRhythm Provides High Value From a Health Economic Perspective
- iRhythm® Technologies Comments on the Final Medicare Physician Fee Schedule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023